The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 11, pp. 1614-1617. DOI 10.1345/aph.1D111
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, A. C.
Right arrow Articles by Chan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, A. C.
Right arrow Articles by Chan, R.

Treatment of Impending Tumor Lysis with Single-Dose Rasburicase

Anselm CW Lee, MBBS FHKAM (Paediatrics)

Senior Medical Officer, Department of Paediatrics, Tuen Mun Hospital, New Territories, Hong Kong, China

Chak H Li, MBChB FHKAM (Paediatrics)

Medical Officer, Department of Paediatrics, Tuen Mun Hospital

Kwan T So, MBBS FHKAM (Paediatrics)

Chief of Service, Department of Paediatrics, Tuen Mun Hospital

Regina Chan, BSc

Pharmacist, Tuen Mun Hospital

Reprints: Anselm CW Lee MBBS FHKAM (Paediatrics), Department of Paediatrics, Tuen Mun Hospital, New Territories, Hong Kong, China, FAX 852-2456-9111, aclee{at}graduate.hku.hk

OBJECTIVE: To report the experience of using rasburicase as a single-dose treatment for childhood leukemia presenting with hyperuricemia.

CASE SUMMARIES: Three children with acute lymphoblastic leukemia presenting with hyperuricemia received rasburicase as a single intravenous dose just prior to the start of chemotherapy. This was followed by rapid reduction of serum uric acid levels within 24 hours, which remained low throughout induction therapy while allopurinol and hydration therapy without urinary alkalinization ensued. Subclinical tumor lysis was evidenced by the appearance of hyperphosphatemia and hypocalcemia in all cases and hyperkalemia in 1 patient. These abnormalities were transient, and each patient's renal function gradually improved from pretreatment baseline without requiring dialysis.

DISCUSSION: Our experience suggests that hyperuricemia in children at risk for tumor lysis can be managed with a briefer regimen of rasburicase than the recommended 5- to 7-day course.

CONCLUSIONS: A shorter course of rasburicase treatment, including single-dose injection, is feasible and will improve the cost-effectiveness profile of the otherwise expensive compound.

Key Words: acute lymphoblastic leukemia, hyperuricemia, rasburicase, tumor lysis syndrome

Published Online, October 1, 2003. www.theannals.com, DOI 10.1345/aph.1D111


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
T. M Arnold, J. P Reuter, B. S Delman, and C. B Shanholtz
Use of Single-Dose Rasburicase in an Obese Female
Ann. Pharmacother., September 1, 2004; 38(9): 1428 - 1431.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.